Observational studyBMC infectious diseases2022
Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study.
Observational study in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- SARS-CoV-2 Breakthrough Infections and Reinfections in Patients with Severe Mental Illness during Three Omicron Outbreaks.Infection & chemotherapy · 2026Article
- Varicella zoster virus infection and reactivation in a psychiatric ward during the COVID-19 pandemic: a case series analysis.Clinical and experimental vaccine research · 2026Article
- Risk factors of COVID-19 breakthrough infection: a case-control test-negative design study.BMC infectious diseases · 2025Article
- Longitudinal analysis of Covid-19 infection trends and in-hospital mortality across six pandemic waves in Tunisia.Archives of public health = Archives belges de sante publique · 2025Article
- Hesitancy towards COVID-19 booster vaccine among healthcare workers in Bangladesh.BMC health services research · 2025Article
- COVID-19 breakthrough infections during the circulation of Delta and Omicron variants in Tirana, Albania, April 2021-March 2022.PloS one · 2025Article
- Impact of pharmaceutical and non-pharmaceutical interventions on COVID-19 in Tunisia.BMC public health · 2024Article
- SARS-CoV-2 Evolution: Immune Dynamics, Omicron Specificity, and Predictive Modeling in Vaccinated Populations.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- SARS-CoV-2 vaccine breakthrough infection and the evaluation of safety precaution practice before and after vaccination among healthcare workers in South West, Nigeria.BMC public health · 2024Article
- Article
- Characteristics Associated with COVID-19 Breakthrough Infections after Booster Vaccinations in Healthcare Workers: Insights from the TüSeRe:exact Study.Journal of clinical medicine · 2024Article
- Results of the Cologne Corona Surveillance (CoCoS) project- a cross-sectional study: survey data on risk factors of SARS-CoV-2 infection, and moderate-to-severe course in primarily immunized adults.BMC public health · 2024Article
- Article
- A study to assess the severity and risk of COVID-19 breakthrough infection in admitted SARS-CoV-2 vaccinated individual.Journal of family medicine and primary care · 2023Article
- Review
- The Good Behaviour Game: Maintaining students' physical distancing in physical education classes during the COVID-19 pandemic.Health education journal · 2023Article
- Clinical Characteristics of Severe COVID-19 Patients During Omicron Epidemic and a Nomogram Model Integrating Cell-Free DNA for Predicting Mortality: A Retrospective Analysis.Infection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe drive to vaccinate large populations is nowadays the main instrument for combating the pandemic and preventing serious disease and death. However, breakthrough infection (post-vaccination infection) still happens after vaccination among fully vaccinated people. We aimed to assess the severity outcomes and to determine its associated factors among vaccinated COVID-19 cases in the governorate of Sousse, Tunisia.
methodsWe carried out a five-month observational longitudinal study including all the population of Sousse. Confirmed infections of SARS-CoV-2 and the vaccination status are recorded in the daily COVID- 19 database of the Regional Office of the Tunisian Ministry of Health. We included all post-vaccination COVID-19 cases for the analysis of the COVID-19 serious outcomes. Data were collected via 15-min telephonic call interviews conducted by trained interviewers. Descriptive analysis with calculating incidence rates of confirmed COVID-19 cases per 100,000 inhabitants was conducted. In binary logistic regression, adjusted odds ratios along with 95% intervals confidence were performed to determine factors related to severe or critical COVID-19.
resultsAs of 31 July 2021, 107,545 persons over 19 years old have received at least one dose of COVID-19 vaccination. Among the vaccinated population, we traced and included 765 breakthrough infection cases, and the incidence rate was 711.3 per week. The majority were female (sex-ratio = 0.8), and the average age of the overall cases was 55.7 years. The prevalence of severe or critical cases in vaccinated COVID-19 patients occurs in 10.8% of cases. Patients with a medical history of cardiovascular diseases had more than two times increased odds to have a severe or critical disease. We also found the highest self-estimation of adherence to preventive measures was inversely correlated to serious cases and having an incomplete vaccination schema was strongly associated with complications.
conclusionsWe tried to provide evidence about the breakthrough infections to improve measures of prevention and control of COVID-19. Boosting immunity for vulnerable patients added to maintaining and promoting preventive measures are not only essential to prevent severe cases of breakthrough infections of COVID-19, but also other influenza-like diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.